Acute Myeloid Leukemia

Relapsed / Refractory

HEMAL0045
Phase 1a/b
CG-806 in
Relapsed/
Refractory Acute
Myeloid Leukemia
PI: Mannis
Sponsor: Pending

HEMAL0051
Phase III
SNDX-5613 in
Relapsed/
Refractory
Leukemias
PI: Mannis
Sponsor: Syndax
Pharmaceuticals, Inc.

HEMAL0052
Phase I/IV IO-202 in
Relapsed / Refractory Acute
Myeloid Leukemia (AML) Patients with
Monocytic Differentiation and in
Relapsed / Refractory Chronic
Myelomonocytic Leukemia (CMML)
Patients
PI: Mannis
Sponsor: Immune-Onc
Therapeutics, Inc.

HEMAL0054
Phase II
Magroliminab
Combinations in
Myeloid
Malignancies
PI: Mannis
Sponsor: Gilead
Sciences, Inc.
Cohort 2

HEMAL0058
Phase I/CC-95251
Alone and in
Combination with
Antineoplastic
Agents in Acute
Myeloid Leukemia and
Myelodysplastic
Syndromes
PI: Mannis
Sponsor: Celgene
Corporation

HEMAL0047
Phase II/II
CC-488
[ONUREG] in
Combination
Treatment in
Acute Myeloid
Leukemia -
OMNIVERSE Trial
PI: Zhang
Sponsor: Celgene
Corporation

HEMAL0059
Phase II/II
IMGN632
Monotherapy
Administered
Intravenously in
CD123-Positive
Acute Myeloid
Leukemia & Other
CD123-Positive
Hematologic
Malignancies
PI: Mannis
Sponsor: ImmunoGen, Inc.

Blastic
Plasmacytoid
Dendritic Cell
Neoplasm

KEY
Pending
Open for Enrollment
Observational Study
Optional Path
Link
Trial Posting
Extension Study
Immunotherapy
Enrollment on Hold